• Optimizing Cancer Assays with MK-1775 (Wee1 Kinase Inhibitor

  2026-07-17

  This article explores real-world laboratory scenarios in which MK-1775 (Wee1 kinase inhibitor, SKU A5755) enables precise, reproducible cell cycle checkpoint abrogation and sensitization of p53-deficient tumor cells. By grounding best practices in published evidence and practical parameters, the guide empowers researchers to leverage reliable performance data and validated protocols for advanced in vitro cancer assays.

• Cy3 NHS ester (non-sulfonated): Technical Guide for Biomolec

  2026-07-16

  Cy3 NHS ester (non-sulfonated) enables precise fluorescent labeling of proteins, peptides, and oligonucleotides for sensitive detection in imaging workflows that tolerate organic solvents. It is not suitable for labeling delicate proteins or workflows requiring aqueous-only conditions. Researchers benefit from its high extinction coefficient and orange emission but must address solubility, handling, and storage constraints for reproducible results.

• Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Synthesis Workf

  2026-07-16

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed for targeted cytotoxic payload release in antibody-drug conjugate (ADC) research. It should be used exclusively in organic solvent-based workflows, avoiding aqueous, diagnostic, or clinical applications to preserve compound integrity and efficacy.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus: Techni

  2026-07-15

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables high-yield synthesis of fluorescent RNA probes for use in research workflows such as in situ hybridization and Northern blotting. It addresses the need for reproducible, sensitive RNA probe labeling when direct Cy3 incorporation is needed. Use is strictly limited to research applications and not suitable for clinical, diagnostic, or therapeutic settings.

• D-Luciferin (Potassium Salt): Enabling Precision Tumor Imagi

  2026-07-15

  Explore how D-Luciferin (potassium salt) empowers in vivo bioluminescence imaging for precision brain tumor research. This article uniquely bridges substrate chemistry, BBB challenges, and nanoparticle delivery—advancing practical assay decisions in neuro-oncology.

• Crizotinib Hydrochloride in Gastric Cancer Assembloids: A Tr

  2026-07-14

  This thought-leadership article explores the mechanistic underpinnings and strategic integration of Crizotinib hydrochloride, a potent ALK kinase inhibitor, within patient-derived gastric cancer assembloid models. Drawing on recent advances in organoid and stromal cell co-culture systems, we contextualize how this compound enables deeper interrogation of oncogenic kinase pathways, informs resistance mechanisms, and accelerates precision oncology workflows. The article distills experimental validation, protocol parameters, and translational guidance for researchers, with a forward-looking perspective on model-driven drug discovery.

• AT-406 (SM-406): Advanced Insights into Targeting IAPs in Ca

  2026-07-14

  Discover the latest mechanistic advances in apoptosis pathway targeting with AT-406 (SM-406), a potent orally bioavailable IAP antagonist. This article uniquely links structural biology breakthroughs to assay optimization in cancer research.

• Heptamethine Cyanine Dye Targets Progesterone Receptor in HR

  2026-07-13

  This study introduces a novel tumor-targeted heptamethine cyanine dye, CA800-PR, that selectively suppresses progesterone receptor activity and induces Golgi fragmentation in hormone receptor-positive breast cancer. These findings suggest an innovative therapeutic approach beyond traditional hormone therapies, with implications for both targeted treatment and mechanistic cell biology.

• Dinaciclib (SCH727965): Multi-CDK Inhibitor in Cancer Resear

  2026-07-13

  Dinaciclib (SCH727965) is a potent, selective inhibitor of CDK1, CDK2, CDK5, and CDK9, enabling precise control of cell cycle arrest and apoptosis in cancer research. Its high solubility in DMSO and efficacy in both in vitro and in vivo models make it a valuable tool for dissecting cyclin-dependent kinase signaling pathways.

• Hypoxia and Immunometabolism in Tumor Microenvironments

  2026-07-12

  This review explores how hypoxia-driven metabolic reprogramming and immune metabolism shape the tumor microenvironment (TME), promoting immunosuppression and supporting malignant progression. The paper provides a detailed mechanistic framework for understanding metabolic adaptation in cancer and highlights the prospects and limitations of targeting TME metabolism in future therapies.

• Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Res

  2026-07-10

  Dehydroabietic acid is a uniquely effective dual PPAR-α/γ agonist, enabling precise control over lipid metabolism and insulin sensitivity in experimental models. This article translates bench data and recent reference breakthroughs into actionable workflows, troubleshooting tips, and assay enhancements for metabolic disorder research.

• Mithramycin A (SKU A4546): Reliable Tool for Cancer & Cardia

  2026-07-09

  This article addresses persistent challenges in cell-based assays and gene expression studies, highlighting how Mithramycin A (SKU A4546) provides reproducible and specific inhibition of transcriptional targets. Bench scientists will find practical strategies for improving assay sensitivity and data reliability using Mithramycin A, with scenario-driven insights grounded in recent literature.

• TMRE Mitochondrial Membrane Potential Assay Kit: Applied Ins

  2026-07-09

  The TMRE mitochondrial Membrane Potential Assay Kit empowers researchers with high-sensitivity detection of ΔΨm, directly supporting apoptosis and mitochondrial function analyses. Its robust workflow, built-in positive control, and compatibility with high-throughput formats make it an indispensable platform for dissecting mitochondrial health and pathology across cell, tissue, and isolated mitochondria models.

• Exendin-4 (Exenatide): Protocol Advances for Beta Cell Resea

  2026-07-08

  Exendin-4 (Exenatide) is revolutionizing type 2 diabetes research through robust, reproducible protocols that directly enhance insulin sensitivity and beta cell function assays. Explore how APExBIO’s Exendin-4 supports innovative workflows, including yeast-based production, and discover troubleshooting strategies for maximizing experimental reliability.

• Strategic NLRP3 Inflammasome Inhibition with MCC950 Sodium

  2026-07-08

  This thought-leadership article explores the mechanistic foundations and translational promise of MCC950 sodium (CRID3 sodium salt) as a selective NLRP3 inflammasome inhibitor. Drawing on recent evidence—including the pivotal role of NLRP3 in astrocyte phenotypic shifts during morphine tolerance—this piece synthesizes biological insight, experimental rigor, and strategic guidance for translational researchers. It provides actionable protocol parameters, situates MCC950 sodium within a competitive research landscape, and offers a forward-looking perspective on targeting NLRP3-associated inflammation in complex disease models.

450 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page